Pfizer, FDA and Cavazzoni
Lilly expands its Zepbound vial offering, as HIMS pulls back on semaglutide, and other biotech news in today's Readout ...
Revolving door is a VERY polite term for Patrizia Cavazzoni's moves. Then again, she has a 25-year history of picking Big Pharma over vulnerable patients. She'll fit right in with Scott Gottlieb.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results